A real-world study finds reduced RAASi-related hyperkalemia risk among at-risk patients initiating SGLT2 inhibitors. Sodium glucose cotransporter 2 inhibitor (SGLT2i) use is associated with lower ...
SGLT2i and GLP-1RA are associated with lower risks of hyperkalemia compared with DPP4i in patients with CKD and type 2 diabetes. Hyperkalemia risks in patients with chronic kidney disease (CKD) and ...
MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...
Hyperkalemia, an electrolyte disorder associated with kidney dysfunction, is relatively common among emergency department (ED) patients and can be life threatening, predominantly due to cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results